SDP Technology

We are excited about our company, SDP Technology, and the potential of our programs to deliver new, innovative anti-cancer drugs.

SDP Technology is a drug discovery and development company focused on commercialising inhibitors of its proprietary cancer target Sphingosine Kinase (SK). The enzyme SK1 has been strongly implicated in a range of disease states, particularly in the development and progression of cancer (eg prostate, lung, breast and colon cancers).

We are well on our way to creating exciting anti-cancer agents for the oncology market and significant value for our shareholders.

Recent News Items

19 Mar 2009

SDP Technology and Alchemia Enter Cancer Drug Collaboration

Australian drug developer, SDP Technology Limited has entered into a drug discovery agreement with Alchemia Limited (ASX:ACL). SDP will have exclusive rights to develop anti-cancer drugs targeting the enzyme sphingosine kinase 1 (SK1) using Alchemia’s VAST chemistry. More

10 Feb 2009

Nature Biotechnology Volume 27 Number 1

Four steps to finding the right people. Of all the ingredients in a biotech start-up, getting the right people involved is most crucial. Here, Ian Brown, CEO of SDP Technology, provides pointers for putting together a successful business team. More

01 Dec 2008

Dr Steve Rietiker joins SDP Board of Directors

SDP is pleased to announce that Dr Steve Rietiker has joined SDP Board of Directors as a Non Executive Director. More